Breast Cancer Patients Diagnosed, Doxorubicin, Melatonin, Vitamin D Concentration
Conditions
Keywords
Vitamin D, Doxorubicin, Cardioprotective Effect, Melatonin, Breast Cancer Patients
Brief summary
This study aims to assess the cardioprotective effect of melatonin and vitamin D in breast cancer patients who receive doxorubicin.
Detailed description
Doxorubicin is one of the most potent chemotherapeutic agents and is widely used for the treatment of various cancers and hematological malignancies . Although Doxorubicin has a potential beneficial effect in cancer treatment, its dose-dependent cardio toxicity is considered a major challenge. Doxorubicin is known to generate free radicals either by redox cycling between a semiquinone form and a quinone form or by forming a Doxorubicin-Fe3+ complex . In both pathways, molecular oxygen is reduced to superoxide ion , which is converted to other forms of reactive oxygen species such as hydrogen peroxide and hydroxyl radical . These free radicals could then cause membrane and macromolecule damage, both of which lead to injury to the heart, an organ that has a relatively low level of antioxidant enzymes such as superoxide dismutase and catalase . Furthermore, it was revealed that Doxorubicin may enhance the death of cardiomyocytes by affecting the tumor necrosis factor signaling pathway via increasing the expression and levels of inflammatory genes interleukin and interleukin -6 . To alleviate DOX-induced toxicity, researchers have tested a number of strategies, including the administration of antioxidants and/or antiapoptotic agents, in both in vitro and in vivo models of Doxorubicin induced cytotoxicity, but most of these trials have failed to translate into clinical benefits . As a result, there are no effective approaches for alleviating Doxorubicin induced cytotoxicity despite intensive research over recent decades . Melatonin is a natural hormone that is primarily secreted by the pineal gland and functions as a major regulator of circadian rhythms in humans . Melatonin also plays a variety of biological roles as a modulator of mood, sexual behavior and sleep; low levels or a deficiency of melatonin are also associated with Parkinson's disease, Alzheimer's disease, epilepsy, ischemic injury, diabetes, and even cancer . Melatonin has emerged as a promising adjuvant that protects against doxorubicin-induced cytotoxicity, as highlighted by various studies and clinical trials that have demonstrated cardioprotective effects against several chemotherapeutic agents . Moreover, melatonin exhibits low toxicity and easily enters cells owing to its good solubility in both aqueous and organic phases and its highly lipophilic properties . Vitamin D plays an important role in the regulation of body function including the cardiovascular system . Vitamin D deficiency results in the decrease of active calcitriol leading to inhibition of proliferation of cardiomyocytes and vascular smooth muscles . This study aims to assess the cardioprotective effect of melatonin and vitamin D in breast cancer patients who receive doxorubicin.
Interventions
30 patients will receive a traditional chemotherapeutic agent (Doxorubicin group) for 12 weeks.
patients with Vitamin D supplementation (1000 iu/day) plus traditional therapy for 12 weeks
patients with 10 mg of melatonin orally, once daily plus traditional therapy for 12 weeks
Sponsors
Study design
Eligibility
Inclusion criteria
* Age from 18 to 65 years old. * Gender: female. * Positive breast cancer women who are scheduled to receive Doxorubicin. * Have a good performance status according to the eastern cooperative oncology group with a score of 0-2. * Normal baseline Echocardiography with left ventricular ejection fraction ≥ 50%. * Normal renal and liver function tests.
Exclusion criteria
* Pregnant or breastfeeding women. * Women with HER-2 positive of breast cancer. * Formerly treated with Doxorubicin. * Patients with a known hypersensitivity to any of the used drugs. * On other concomitant vitamins or food supplements. * Valvular heart disease, coronary artery disease, history of congestive heart failure or cardiomyopathy. * Impaired Left ventricular systolic function in which the Left Ventricular Ejection Fraction \< 50%.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Decreasing incidence and severity of cardiotoxicity | 12 weeks | Assessment of decreasing incidence and severity of cardiotoxicity by echocardiogram and ejection fraction is associated with doxorubicin treatment. |
Secondary
| Measure | Time frame |
|---|---|
| change in the serum level of the (biological markers). | 12 weeks |
Countries
Egypt